Gastrointestinal stromal tumor (GIST) presenting as a multilocular cystic intra-abdominal mass in a dog

John Edward Blaxill1*, Hannah Bender2, Qicai Jason Hoon3, Jia Wen Sow4, Katrina Y. Cheng1 and Peter Francis Bennett1

Abstract

Background: Gastrointestinal stromal tumor (GIST) is a malignant mesenchymal neoplasm described in humans, dogs, and cats. A hallmark of diagnosis for GISTs is positive immunohistochemical labelling with c-Kit (CD117). The differentiation of GIST from other mesenchymal neoplasms of the gastrointestinal tract is pivotal to allow for initiation of appropriate treatment. In humans, cystic GIST has been described, though this has not been reported in dogs. In humans, the cystic form of GIST has been associated with a favorable prognosis. In the present paper, we report a case of multilocular cystic GIST in a dog, which has not previously been described in this species.

Case presentation: A ten-year-old, male-entire Maltese terrier mix breed dog presented with a large cystic mural mass of the duodenum and orad jejunum. Histopathology and positive immunohistochemical staining with CD117 confirmed a diagnosis of GIST. No evidence of metastasis was detected on routine staging with abdominal sonography and thoracic radiography at the time of diagnosis. Surgical resection was performed and toceranib therapy was initiated post-operatively. Metastasis was documented 251 days after surgery on computed tomography. Due to clinical deterioration, the patient was humanely euthanised 370 days after surgical excision.

Conclusions: There are few differential diagnoses for large multilocular cystic intra-abdominal masses in dogs. This case presents a previously undescribed presentation of gastrointestinal stromal tumor in the dog as a predominantly multilocular cystic mass. It remains unclear if the cystic form of GIST may represent a favorable prognosis in dogs.

Keywords: Mesenchymal, Neoplasia, Abdominal, Peritoneal, c-Kit, CD117, Toceranib, Cyst

Background

Mesenchymal tumors account for 10 – 30% of neoplasms in the gastrointestinal tract of dogs [1, 2]. The most common of these are leiomyosarcoma and gastrointestinal stromal tumor (GIST), with each accounting for around half of cases reported in dogs [1–3].

GISTs most often occur in the small intestine and cecum of dogs, though in humans these are more common in the stomach [4]. GISTs are typically solid neoplasms, though rare presentations of predominantly cystic neoplasms are reported in humans [5]. Cystic GISTs have not previously been described in the veterinary literature. This report describes a case of GIST with predominant cystic change in a dog.
Case report

A 10-year-old, male entire, Maltese terrier mix breed dog presented with a three-month history of slowly progressive abdominal distension. The patient was reported to vomit bilious material daily for two weeks prior to presentation and had no other significant clinical history. Physical examination identified abdominal distension with no overtly palpable abdominal mass effect, a grade IV/VI left-sided apical systolic cardiac murmur and generalized moderate muscle atrophy.

Echocardiographic examination identified chronic degenerative mitral valve disease, most consistent with myxomatous mitral valve disease. Sonographic examination of the abdominal cavity identified a markedly expansile, heterogeneously echogenic, well-vascularized soft tissue mass with multiloculated cystic structures containing anechoic fluid admixed with echogenic particulate matter (Fig. 1). The origin of the mass could not be determined. The mass extended cranially to the level of the liver, caudally to the level of the bladder, and dorsally to the level of the kidneys. Other findings included a mild reduction of renal corticomedullary definition bilaterally, diffusely hypechoic hepatic parenchyma, and a symmetrically enlarged prostate with cystic areas. The remainder of the abdominal sonographic examination was unremarkable. Thoracic radiography identified no abnormalities.

Abdominocentesis removed 700 mL of transparent straw-colored fluid, identified as transudate (protein 26 g L$^{-1}$) with low numbers of large mononuclear cells ($120 \times 10^6$ cells L$^{-1}$). The cellular population of the abdominal fluid consisted of large mononuclear cells with vacuolated grey to light blue cytoplasm, with a round, irregular medium to large nucleus most likely of monocytic lineage. Complete blood count and serum biochemical analysis were unremarkable. Resting ammonia was within reference range. Prothrombin time and activated partial thromboplastin time were within normal limits.

A multiloculated cystic mass arising from the duodenum and oral portion of the jejunum with omental adhesions was identified during ventral midline celiotomy (Fig. 2). The longest diameter of the mass measured approximately 20 cm. The adhesions were broken down and the mass was resected with 5 cm orad and aborad margins. A functional end-to-end stapled anastomosis of the duodenojejunal segment was performed. A focal nodule identified within the left lateral liver lobe was biopsied. The remainder of the peritoneal cavity examination was unremarkable.

Histopathologic examination identified an unencapsulated, cavitated mass composed of monomorphic mesenchymal cells arranged in interlacing streams and loosely organised herringbone patterns with variable collagenous or myxoid matrix. Empty cystic spaces multifocally scattered throughout the mass were not lined by epithelial cells (Fig. 3A). Neoplastic cells were characterised by indistinct margins, small amounts of vacuolated, amphophilic cytoplasm and oval-shaped nuclei with marginated chromatin and small, centrally located nucleoli. Anisocytosis and anisokaryosis were mild, and the mitotic count was five per 10 high power fields (equivalent to 2.37mm$^2$). A preliminary diagnosis of nonangiogenic, nonlymphogenic intestinal mesenchymal tumor (NIMT) was made based on histopathology alone. NIMTs are a subset of poorly defined intestinal sarcomas that require immunohistochemistry (IHC) for further classification between the primary differential diagnoses of GIST and leiomyosarcoma. In this case, IHC for CD117 and smooth muscle actin were required to distinguish between primary differential diagnoses of GIST and leiomyosarcoma, and exclude less likely differentials including fibroblastic and neural tumors.

IHC for CD117 demonstrated moderate-to-strong membranous labelling of greater than 95% of neoplastic cells (Fig. 3B). IHC for smooth muscle actin yielded variable cytoplasmic staining among neoplastic cells (Fig. 3C). GIST was diagnosed based on positive immunolabelling with CD117.

Hepatic biopsies identified no metastatic disease. Mild hepatocellular glycogen accumulation and lipogranuloma formation, considered incidental findings, accounted for the gross appearance of the liver during surgery. Hepatic biopsy specimens were submitted for bacterial culture and sensitivity due to pale-yellow discoloration of the gross appearance of the liver during surgery. Aerobic and anaerobic bacterial culture of hepatic tissue identified no bacterial growth. The patient was started on toceranib at 3.0 mg kg$^{-1}$ orally three times per week on a Monday, Wednesday, and Friday dosing schedule. No local disease recurrence or metastasis was noted on examination 78 days after starting toceranib.

Metastasis of GIST was strongly suspected at recheck examination 251 days after surgery based on computed tomographic imaging, which identified multiple peritoneal nodular changes and a small volume of encapsulated peritoneal effusion (Fig. 4). No evidence of pulmonary metastasis, and no local recurrence at the duodenojejunal

---

1 IDEXX ProCyte Dx® Hematology Analyzer
2 IDEXX Catalyst Dx® Chemistry Analyzer
3 IDEXX Catalyst One Chemistry Analyser
4 IDEXX Coag Dx Analyser
5 EndoGIA 60mm, TA60mm Autosuture, Medtronic, Auckland

---

6 Palladia®; Zoetis, Madison, NJ, USA
enterectomy site was identified on computed tomography. Toceranib was discontinued approximately two months prior to this recheck examination and diagnostic imaging study due to owner non-compliance; the patient had a one-month history of mild lethargy prior to the recheck. Peritoneal fluid analysis identified a macrophagic exudate without evidence of neoplastic cells. No specific sampling of the suspected metastatic lesions was performed due to an inability to access these sites safely.

The patient was re-initiated on toceranib at 3.0 mg kg$^{-1}$ three times per week on a Monday, Wednesday, and Friday dosing regimen at the time of suspected metastasis. There was initial improvement in clinical signs of lethargy after re-initiation of therapy. The patient later presented for worsening lethargy and anorexia of one week duration, and owners elected for humane euthanasia due to a poor prognosis. The overall survival time was 370 days. Post-mortem examination was declined by the owners.

**Discussion and conclusion**

This report highlights an important differential diagnosis for a predominantly cystic mass within the abdominal cavity of dogs. Differential diagnoses for dogs with
intra-abdominal cystic lesions include cystic lymph nodes, congenital duplication cysts, pancreatic pseudocyst, paraprostatic cysts, cystic lesions of the female reproductive tract, parasitic disease, and cystic neoplastic disease. These conditions are generally localized, whereas this case was expansile without clear lesion localisation prior to exploratory celiotomy.

It is speculated that GISTs arise from the interstitial cells of Cajal, which are pivotal to coordination and propagation of intestinal slow waves and allow transduction of neural inputs from the enteric nervous system [6]. These are generally solid neoplasms of spindle cells arising from the gastrointestinal tract of dogs which can be differentiated immunohistochemically from other intestinal mesenchymal neoplasms by positive expression of the type III tyrosine-protein kinase c-Kit (CD117) and discovered-on-GIST-1 (DOG-1) [2, 3, 7].

In humans, it has been speculated that cystic lesions of GISTs may occur due to (a) rapidly expansile growth pattern in which cystic structures occupy the predominant tumor volume, (b) rapid growth or tissue hypoxia with subsequent necrosis (cystic degeneration), (c) cystic metastatic lesions to other organs or omentum, or (d) gross disease treated with appropriate effective therapy in which subsequent cystic lesions develop due to tumor regression [8]. The mechanisms underlying the cystic growth pattern of this neoplasm were not evident on histologic examination. The initial protracted clinical course was suggestive of slow tumor growth; however, cystic degeneration associated with poor vascularization and tissue hypoxia could not be excluded. Interestingly, on computed tomography at time of recheck examination, suspected metastatic lesions also had a cystic structure, implicating a cystic growth pattern in the pathobiology of this mass.

Applying the modified National Institutes of Health (NIH) consensus criteria for defining postsurgical risk of recurrence in humans with GIST, this patient was classified as “high-risk” due to large tumor diameter and mitotic count (>10/50hpf), and adjuvant tyrosine kinase inhibitor therapy was recommended [9]. Mitotic count has been identified as a prognostic indicator for canine GIST; however, based on the NIH consensus criteria most canine GIST would be classified as “high risk” due to mitotic count alone, and further work to establish risk categories specific for canine patients is recommended [1, 10].

Although imatinib therapy remains the mainstay of treatment of high-risk GISTs in people and has been reported with success in individual dogs, hepatotoxicity is reported in dogs even at low doses which precludes its routine administration [11–13]. Sunitinib is another multi-targeted receptor tyrosine kinase inhibitor that has

**Fig. 3**  A The mass is composed of neoplastic mesenchymal cells arranged into delicate streams that intersect multilocular, empty cystic spaces. Inset: On higher magnification, neoplastic spindle cells have indistinct cell margins, scant vesicular cytoplasm and oval-shaped nuclei with small, centrally located nuclei.  B IHC for CD117. Moderate membranous labelling is detected in the majority neoplastic cells.  C IHC for smooth muscle actin. Light cytoplasmic labelling is present in rare neoplastic cells.

**Fig. 4** Sagittal plane computed tomographic image identifying an abnormal cystic structure of the cranial abdomen (red arrow) and encapsulated peritoneal effusion (red triangle) at time of suspected disease progression (metastasis).
shown benefit in people who progress despite imatinib therapy [14]. Imatinib, sunitinib and toceranib share affinity for the tyrosine-protein kinase (KIT) receptor, which is the pivotal molecular target of therapy in GIST. As such, toceranib is considered a viable alternative in dogs with similar molecular targets to imatinib and has shown promise in the treatment of GIST in dogs [10, 15].

Despite the NIH “high-risk” designation in 85% of human patients with cystic GIST in one report, the 5-year recurrence rate was only 6.6% [5]. In that same study, a control group of patients with solid GISTs showed a 5-year recurrence rate of 33.9%, significantly higher than those with cystic GISTs [5]. The authors concluded that cystic GISTs may display a relatively indolent behavior and have a favorable prognosis in humans [5]. It is unclear if this advantage is also seen in canine patients.

Gain of function mutations in *c-kit* exon 11 have recently been identified in up to 35% canine GISTs by PCR, and 74% by RT-PCR [16, 17]. The juxtamembrane domain of exon 11 is highly conserved between humans and dogs, being 100% homologous between species [3]. In humans, mutations in *c-kit* are reported in 80 – 85% of GISTs, though a recent publication of cystic GISTs identified *c-kit* mutation in only 45% of patients [4, 5]. It is possible that *c-kit* mutations are less common in human cystic GISTs, though larger studies are required to confirm this finding.

Human patients with mutations of *c-kit* exon 11 appear to have improved response to imatinib therapy, with poorer responses reported for mutations of *c-kit* exon 9 or 17 [18]. However, up to 45% of human wild-type GISTs may respond to imatinib therapy, hence even without identified *c-kit* mutation tyrosine kinase inhibitor therapy may be of benefit [19]. It remains unclear whether genotype analysis and assessment of *c-kit* mutation holds prognostic significance in canine GIST. This patient did not have genotyping performed, as it would not have changed the treatment recommendation or prognostic information based on current veterinary literature.

In conclusion, GIST should be considered as a differential diagnosis in canine patients identified with predominantly cystic lesions within abdominal cavity. The prognosis for these lesions may be improved in comparison to solid GIST lesions based on human literature, though the significance in canine patients remains unclear.

**Acknowledgements**

Dr Wilson So, Veterinary Pathology Diagnostic Services, McMaster Building B14, The University of Sydney, NSW, 2006 for providing photographs of histopathology slides.

**Authors’ contributions**

JEB drafted the manuscript and was involved in the ongoing care of the patient at the time of clinical deterioration. HB was responsible for the anatomical pathological interpretation. QJH performed the surgical excision for the patient. JWS performed and interpreted the diagnostic imaging procedures. KYC saw the patient at initial presentation to the referral institution and instigated initial diagnostic and therapeutic intervention. PFR was the lead investigator and responsible for final editing of the document. All authors have read and reviewed the manuscript, and had appropriate input to their relevant components of the case report.

**Funding**

No funding was sought for this case report.

**Availability of data and materials**

Data sharing is not considered applicable to this publication, as no datasets were generated or analysed in the creation of this case report.

**Declarations**

**Ethics approval and consent to participate**

To the best of the authors’ knowledge, this patient was clinically managed according to the contemporary standard of care for the treatment of GIST in dogs based on the literature currently available. All treatments were instigated by a licensed veterinarian. Informed owner consent was obtained prior to all diagnostic testing and treatments provided to the patient. No ethics approval was required for this retrospective evaluation.

**Consent for publication**

Informed consent was obtained from the owner or legal custodian of all animal(s) described in this work for the procedure(s) undertaken. No animals or humans are identifiable within the publication, and therefore additional informed consent for publication was not required.

**Competing interests**

The authors declare that they have no competing interests.

**Author details**

1. University of Sydney Veterinary Teaching Hospital, Evelyn Williams Building B10, 65 Paranatta Road, Camperdown, New South Wales 2050, Australia. 2. Veterinary Pathology Diagnostic Services, McMaster Building B14, The University of Sydney, NSW, 2006 for providing photographs of histopathology slides.

1. Del Alcazar CM, Mahoney JA, Dittrich K, Stefanovski D, Church ME. Outcome, prognostic factors and histological characterization of canine gastrointestinal sarcomas. Vet Comp Oncol. 2021;19(3):578–86.

2. Russell KN, Mehler SJ, Skorupski KA, Baez JL, Shofer FS, Goldschmidt MH. Clinical and immunohistochemical differentiation of gastrointestinal stromal tumors from leiomyosarcomas in dogs: 42 cases (1990–2003). J Am Vet Med Assoc. 2007;230(9):1329–33.

3. Frost D, Lasota J, Miettinen M. Gastrointestinal stromal tumors from leiomyosarcomas in dogs: 42 cases (1990–2003). J Vet Med Sci. 2003;65(11):1329–33.

4. Lasota J, Miettinen M. KIT and PDGFRA mutations in gastrointestinal stromal tumors (GISTs). Semin Diagn Pathol. 2006;23(2):91–102.

**References**

1. Del Alcazar CM, Mahoney JA, Dittrich K, Stefanovski D, Church ME. Outcome, prognostic factors and histological characterization of canine gastrointestinal sarcomas. Vet Comp Oncol. 2021;19(3):578–86.

2. Russell KN, Mehler SJ, Skorupski KA, Baez JL, Shofer FS, Goldschmidt MH. Clinical and immunohistochemical differentiation of gastrointestinal stromal tumors from leiomyosarcomas in dogs: 42 cases (1990–2003). J Am Vet Med Assoc. 2007;230(9):1329–33.

3. Frost D, Lasota J, Miettinen M. Gastrointestinal stromal tumors and leiomyomas in the dog: a histopathologic, immunohistochemical, and molecular genetic study of 50 cases. Vet Pathol. 2003;40(1):42–54.

4. Lasota J, Miettinen M. KIT and PDGFRA mutations in gastrointestinal stromal tumors (GISTs). Semin Diagn Pathol. 2006;23(2):91–102.
5. Xue A, Yuan W, Gao X, Fang Y, Shu P, Xu C, Li H, Xu Y, Song Q, Hou Y, Shen K. Gastrointestinal stromal tumors (GISTs) with remarkable cystic change: a specific subtype of GISTs with relatively indolent behaviors and favorable prognoses. J Cancer Res Clin Oncol. 2019;145(6):1559–68.

6. Al-Shboul GA. The importance of interstitial cells of cajal in the gastrointestinal tract. Saudi J Gastroenterol. 2013;19(1):3–15.

7. Dailey DD, Ehrrhart EJ, Duval DL, Bass T, Powers BE. DOG1 is a sensitive and specific immunohistochemical marker for diagnosis of canine gastrointestinal stromal tumors. J Vet Diagn Invest. 2015;27(3):268–77.

8. Bechtold RE, Chen MY, Stanton CA, Savage PD, Levine EA. Cystic changes in hepatic and peritoneal metastases from gastrointestinal stromal tumors treated with Gleevec. Abdom Imaging. 2003;28(6):808–14.

9. Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol. 2008;39(10):1411–9.

10. Berger EP, Johannes CM, Jergens AE, Allenspach K, Powers BE, Du Y, Mochel JP, Fox LE, Musser ML. Retrospective evaluation of toceranib phosphate (Palladia®) use in the treatment of gastrointestinal stromal tumors of dogs. J Vet Intern Med. 2018;32(6):2045–53.

11. Irie M, Takeuchi Y, Ohtake Y, Suzuki H, Nagata N, Miyoshi T, Kagawa Y, Yamagami T. Imatinib mesylate treatment in a dog with gastrointestinal stromal tumors with a c-kit mutation. J Vet Med Sci. 2015;77(11):1535–9.

12. Kobayashi M, Kuroki S, Ito K, Yasuda A, Sawada H, Ono K, Washizu T, Bonkobara M. Imatinib-associated tumour response in a dog with a non-resectable gastrointestinal stromal tumour harbouring a c-kit exon 11 deletion mutation. Vet J. 2013;198(1):271–4.

13. London CA. Tyrosine kinase inhibitors in veterinary medicine. Top Companion Anim Med. 2009;24(3):106–12.

14. Mulet-Margalef N, Garcia-Del-Muro X. Sunitinib in the treatment of gastrointestinal stromal tumor: patient selection and perspectives. Onco Targets Ther. 2016;9:7573–82.

15. London CA. Small molecule inhibitors in veterinary oncology practice. Vet Clin North America Small Anim Pract. 2014;44(5):893–908.

16. Gregory-Bryson E, Bartlett E, Kiupel M, Hayes S, Yuzbasiyan-Gurkan V. Canine and human gastrointestinal stromal tumors display similar mutations in c-KIT exon 11. BMC Cancer. 2010;10:559.

17. Takanosu M, Amano S, Kagawa Y. Analysis of c-KIT exon 11 mutations in canine gastrointestinal stromal tumours. Vet J. 2016;207:118–23.

18. Takahashi T. Genetics. In: Kurokawa Y, Komatsu Y, editors. Gastrointestinal Stromal Tumor. Singapore: Springer; 2019. p. 31–48.

19. Testuhito M, Komatsu Y. Genetics. In: Kurokawa Y, Komatsu Y, editors. Gastrointestinal Stromal Tumor. Singapore: Springer; 2019. p. 79–87.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.